Citadel Advisors’s Turn Therapeutics TTRX Stock Holding History

Citadel Advisors’s Portfolio TTRX Stock Details TTRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,986	Closed	-$82.7K	–	14807
2025 Q4	$82.7K	Buy	+20,986	New	+$87.5K	﹤0.01%	11782

Other funds holding TTRX

DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TTRX Position: Q1 2026 in Review

Citadel Advisors sold out of Turn Therapeutics (TTRX) in Q1 2026, closing a stake of 20,986 shares — an estimated $82.7K sold.

Citadel Advisors first reported a position in TTRX in Q4 2025 and held it in 1 quarter. The position peaked at $82.7K in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

Citadel Advisors reported no remaining Turn Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 20,986 Turn Therapeutics shares in Q1 2026, an estimated $82.7K.
Citadel Advisors first reported a position in Turn Therapeutics in Q4 2025 and held it in 1 quarter.
Citadel Advisors's Turn Therapeutics position peaked at $82.7K in Q4 2025.
20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.